Clovis Oncology (CLVS) Bounces Off Lows, Remains Down 13.8%
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Clovis Oncology (NASDAQ: CLVS) is bouncing off earlier lows as analysts at Piper Jaffray defend the name following this morning's data which was sub-par to a competitor's. Shares are up 13.8% after trading down nearly 30% earlier.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chardan Capital Markets Starts Clovis Oncology (CLVS) at Sell
- T-Mobile (TMUS) PT Raised to $46 at Nomura, Remains Sidelined
- T-Mobile (TMUS) PT, Estimates Raised at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!